Patents Assigned to Faes Farma, S.A.
-
Patent number: 11642309Abstract: The invention relates to an aqueous pharmaceutical composition comprising: a) bilastine or a pharmaceutically acceptable salt or solvate thereof, b) mometasone, or a pharmaceutically acceptable derivative thereof, c) a suspending agent, and d) 2-hydroxypropyl-?-cyclodextrin; wherein the pH of the aqueous pharmaceutical composition is between 3.5 and 5.5, and wherein the content of 2-hydroxypropyl-?-cyclodextrin is less than 8.5% by weight. The invention also relates to said compositions for use in the treatment and/or prevention of a disorder or disease susceptible to amelioration by antagonism of H1 histamine receptor and/or of a corticosteroid-responsive disease through nasal administration. The invention also relates to a process for preparing the aqueous pharmaceutical composition above mentioned.Type: GrantFiled: October 15, 2018Date of Patent: May 9, 2023Assignee: FAES FARMA, S.A.Inventors: Gonzalo Hernández Herrero, Ana Gonzalo Gorostiza, Neftalí García Domínguez, Arturo Zazpe Arce, Pablo Morán Poladura, Tania González García
-
Publication number: 20210186869Abstract: The invention relates to an aqueous pharmaceutical composition comprising: a) bilastine or a pharmaceutically acceptable salt or solvate thereof, b) mometasone, or a pharmaceutically acceptable derivative thereof, c) a suspending agent, and d) 2-hydroxypropyl-?-cyclodextrin; wherein the pH of the aqueous pharmaceutical composition is between 3.5 and 5.5, and wherein the content of 2-hydroxypropyl-?-cyclodextrin is less than 8.5% by weight. The invention also relates to said compositions for use in the treatment and/or prevention of a disorder or disease susceptible to amelioration by antagonism of H1 histamine receptor and/or of a corticosteroid-responsive disease through nasal administration. The invention also relates to a process for preparing the aqueous pharmaceutical composition above mentioned.Type: ApplicationFiled: October 15, 2018Publication date: June 24, 2021Applicant: FAES FARMA, S.A.Inventors: Gonzalo HERNÁNDEZ HERRERO, Ana GONZALO GOROSTIZA, Neftalí GARCÍA DOMÍNGUEZ, Arturo ZAZPE ARCE, Pablo MORÁN POLADURA, Tania GONZÁLEZ GARCÍA
-
Patent number: 10525018Abstract: The present invention relates to calcifediol soft capsules, to their use in the treatment or prevention of diseases related to vitamin D deficiency, such as vitamin D deficiency, demineralization such as hypocalcemia and hypophosphatemia, renal osteodystrophy, rickets, osteoporosis, osteopenia, osteoarthritis, osteoarthrosis, osteomalacia, hypoparathyroidism, and inflammatory bowel disease, and to their process of manufacture.Type: GrantFiled: February 5, 2016Date of Patent: January 7, 2020Assignee: FAES FARMA, S.A.Inventors: Josep María Suñé Negre, Ignacio Ortega Azpitarte, Pepa Del Arenal Barrios, Gonzalo Hernández Herrero
-
Patent number: 10106522Abstract: The invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, a method of synthesis of said compounds, pharmaceutical compositions comprising them and their use in the treatment and/or prevention of conditions mediated by H1 histamine receptor, such as allergic disorders or diseases.Type: GrantFiled: December 28, 2015Date of Patent: October 23, 2018Assignee: Faes Farma, S.A.Inventors: Rosa Rodes Solanes, Roberto Olivera Tizne, Gonzalo Hernández Herrero, Víctor Rubio Royo, Francisco Ledo Gómez
-
Publication number: 20130296346Abstract: The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, prodrug or solvate thereof, a method of synthesis of said compounds, pharmaceutical compositions comprising them and their use as a medicament for treating inflammatory diseases.Type: ApplicationFiled: November 22, 2011Publication date: November 7, 2013Applicant: Faes Farma, S.A.Inventors: Rosa Rodes Solanes, Neftali Garcia Dominguez, Beatriz Lopez Ortega, Melchor Alvarez De Mon Soto, Antonio De La Hera Martinez, Ana Munoz Munoz, Francisco Ledo Gomez
-
Patent number: 8492411Abstract: A compound of formula (I): or a pharmaceutically acceptable salt, prodrug and/or solvate thereof, and a method for the treatment of an acute or chronic inflammatory disease by inhibiting the production of at least one pro-inflammatory cytokine selected from TNF-alpha, IFN-gamma, IL-8 and IL-10, involving administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (I) as defined above.Type: GrantFiled: July 17, 2010Date of Patent: July 23, 2013Assignee: Faes Farma, S.A.Inventors: Victor Rubio Royo, Antonio De La Hera Martinez, Melchor Alvarez De Mon Soto, Ana Munoz Munoz
-
Publication number: 20130131079Abstract: The present invention is directed to a compound of formula (I) for use in a method to treat or ameliorate amyloid or tau pathologies, such as Alzheimer's disease, or symptoms thereof. The invention is also directed to new compounds of formula (I), of subformula (II), (III), (IV), or (V).Type: ApplicationFiled: May 23, 2011Publication date: May 23, 2013Applicant: FAES FARMA, S.A.Inventors: Francisco Ledo Gómez, Ana Muñoz Muñoz, Carmen Pumar Durán
-
Publication number: 20100305164Abstract: A compound of formula (I): or a pharmaceutically acceptable salt, prodrug and/or solvate thereof, and a method for the treatment of an acute or chronic inflammatory disease by inhibiting the production of at least one pro-inflammatory cytokine selected from TNF-alpha, IFN-gamma, IL-8 and IL-10, involving administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (I) as defined above.Type: ApplicationFiled: July 17, 2010Publication date: December 2, 2010Applicant: Faes Farma, S.A.Inventors: VICTOR RUBIO ROYO, Antonio De La Hera Martinez, Melchor Alvarez De Mon Soto, Ana Munoz Munoz
-
Patent number: 7781594Abstract: The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt, prodrug and/or solvate thereof, and to a method for the treatment an acute or chronic inflammatory disease by inhibiting the production of at least one pro-inflammatory cytokine selected from TNF-alpha, IFN-gamma, IL-8 and IL-10, which comprises administering to a patient who needs such treatment a therapeutically effective amount of a compound of formula (I) as defined above.Type: GrantFiled: June 16, 2008Date of Patent: August 24, 2010Assignee: Faes Farma, S.A.Inventors: Victor Rubio Royo, Antonio De La Hera Martinez, Melchor Alvarez De Mon Soto, Ana Munoz Munoz
-
Publication number: 20100004285Abstract: Crystalline form 1 4-[2-[4-[1 -(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1-piperidinyl]-ethyl]-??-dimethyl-benzeneacetic acid of formula (I) is described, procedures for its preparation, pharmaceutical formulae containing crystalline form 1 and the use of crystalline form 1 to treat allergic reactions and pathological processes mediated by histamine in mammals such as man.Type: ApplicationFiled: September 16, 2009Publication date: January 7, 2010Applicant: FAES FARMA, S.A.Inventors: Aurelio Orjales Venero, Maravillas Bordell Martin, Gonzalo Canal Mori, Haydee Blanco Fuente, Maria Luisa Lucero De Pablo, Victor Rubio Royo, Ramon Mosquera Pestaña
-
Publication number: 20100004283Abstract: The present patent application is directed to 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonic acid salt (formula I), its synthesis and use in the manufacture of a medicament for the treatment and/or prevention of a serotonine and/or norepinephrine mediated disease or condition. The present invention is also directed to pharmaceutical compositions comprising the same.Type: ApplicationFiled: April 12, 2007Publication date: January 7, 2010Applicant: FAES FARMA, S.A.Inventors: Aurelio Orjales Venero, Ramon Mosquera Pestana, Maria Carmen Pumar Duran, Antonio Toledo Avello, Gonzalo Canal Mori, Maravillas Bordell Martin
-
Publication number: 20090312376Abstract: The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt, prodrug and/or solvate thereof, and to a method for the treatment an acute or chronic inflammatory disease by inhibiting the production of at least one pro-inflammatory cytokine selected from TNF-alpha, IFN-gamma, IL-8 and IL-10, which comprises administering to a patient who needs such treatment a therapeutically effective amount of a compound of formula (I) as defined above.Type: ApplicationFiled: June 16, 2008Publication date: December 17, 2009Applicant: FAES FARMA, S.A.Inventors: Victor Rubio Royo, Antonio De La Hera Martinez, Melchor Alvarez De Mon Soto, Ana Munoz Munoz
-
Patent number: 7612095Abstract: Crystalline form 1 of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1 -piperidinyl]ethyl]-??-dimethyl-benzen?eacetic acid Crystalline form 1 of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1 -piperidinyl]ethyl]-??-dimethyl-benzen?eacetic acid of formula (I) is described, procedures for its preparation, pharmaceutical formulae containing crystalline form 1 and the use of crystalline form 1 to treat allergic reactions and pathological processes mediated by histamine in mammals such as man.Type: GrantFiled: April 19, 2002Date of Patent: November 3, 2009Assignee: Faes Farma, S.A.Inventors: Aurelio Orjales Venero, Maravillas Bordell Martin, Gonzalo Canal Mori, Haydee Blanco Fuente, Maria Luisa Lucero De Pablo, Victor Rubio Royo, Ramon Mosquera Pestaña